Characterization of mRNA 5’ capping products using an LC-HRAM-MS/MS analytical platform and Thermo Scientific BioPharma Finder software solution
Production of non-natural mRNA transcripts by IVT for vaccines and therapeutics development and manufacturing requires the addition of the modified cap structure post purification. 2 In eukaryotic systems, non-mitochondrial mRNA are capped at the 5’ end by an inverted 7 methylguanosine (m7G) joined to the transcript by a 5’ to 5’ triphosphate linkage, m7G(5’)ppp(5’)N, referred to as Cap(0). 3–5 Once added to the transcript, the firstnucleotide in the strand, (N), is then methylated at the 2’ hydroxyl position to give the Cap(1) structure, m7G(5’)ppp(5’)Nm.
White Paper from 
If your Download does not start Automatically, Click Download Whitepaper